Aranesp Versus Procrit: Amgen Will Submit Comparative Data to CMS
Executive Summary
Amgen expects to present data demonstrating that front-loaded doses of the anemia agent Aranesp have advantages over standard doses of Johnson & Johnson's Procrit in cancer patients by year-end
You may also be interested in...
Aranesp Fallout: Managed Care May Follow CMS In “Functional Equivalence”
Managed care organizations may start using functional equivalence as a tool in determining coverage levels, biotech companies agreed during a panel presentation at the Kellogg Biotech Conference in Chicago April 5
Aranesp Fallout: Managed Care May Follow CMS In “Functional Equivalence”
Managed care organizations may start using functional equivalence as a tool in determining coverage levels, biotech companies agreed during a panel presentation at the Kellogg Biotech Conference in Chicago April 5
“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?
The Centers for Medicare & Medicaid Services' "functionally equivalent" determination for Aranesp versus Procrit may be a useful model for value-based purchasing by Medicare in the future, a report by the Medicare Payments Advisory Commission suggests